fbpx

Webinar

Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy

by Dr. Julie Nonnekes, Erasmus MC

This talk describes the extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. In vivo imaging was performed on the MILabs VECTorCT imaging platform.

Took place: November, 2020

Share on facebook
Share on Facebook
Share on linkedin
Share on Linkedin
Share on email
Share via Email
Share on whatsapp
Share via WhatsApp
Scroll to Top